Celgene’s Velcade (bortezomib), Revlimid (lenalidomide) and Darzalex (daratumumab) and dexamethasone plus with low dose cyclophosphamide, and in conjunction with an autologous stem cell transplant.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Rituximab and cyclophosphamide are equally effective in achieving remission or low disease activity rates in childhood-onset antineutrophil cytoplasmic antibody–associated vasculitis (AAV), and ...

Get detailed information on Cyclophosphamide, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

Sanofi’s market cap boost coincided with an FDA approval for first-line multiple myeloma drug Sarclisa and nods in Europe and the U.S. for anti-inflammatory juggernaut Dupixent to treat chronic ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in the Sanofi ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.

Also make sure to check our part 1 of our exclusive interview with her regarding the recent FDA approval of isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide ...

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Suzanne is a ...

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) ...